Denali Therapeutics (DNLI) Asset Utilization Ratio (2018 - 2026)
Denali Therapeutics (DNLI) posted quarterly Asset Utilization Ratio of 0.0 for Q2 2024, down 99.67% year-over-year from 0.25 in Q3 2023, and down 99.62% quarter-over-quarter from 0.22 in Q1 2024.
Denali Therapeutics (DNLI) Asset Utilization Ratio (2018 - 2026) Analysis & Trends
Denali Therapeutics (DNLI) has reported Asset Utilization Ratio for 7 consecutive years, with 0.0 the latest figure, recorded in Q2 2024.
- In Q2 2024, Asset Utilization Ratio fell 99.67% year-over-year to 0.0; the TTM figure through Jun 2024 stood at 0.0 (down 99.67% YoY), while the FY2023 annual figure was 0.25, up 244.71% from the prior year.
- Asset Utilization Ratio retreated to 0.0 in Q2 2024 per DNLI's latest filing, from 0.22 in the prior quarter.
- Across five years, Asset Utilization Ratio topped out at 0.28 in Q4 2023 and bottomed at 0.0 in Q2 2024.
- Historically, Asset Utilization Ratio has averaged 0.14 across 5 years, with a median of 0.12 in 2022.
- Annual changes were most pronounced in 2021 — Asset Utilization Ratio surged 904.98% — and 2024, when it sank 99.67%.
- Denali Therapeutics' Asset Utilization Ratio stood at 0.25 in 2020, then tumbled by 78.31% to 0.05 in 2021, then surged by 49.2% to 0.08 in 2022, then soared by 244.1% to 0.28 in 2023, then sank by 99.7% to 0.0 in 2024.
- Business Quant data shows DNLI's Asset Utilization Ratio at 0.0 in Q2 2024, 0.22 in Q1 2024, and 0.28 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 0.47 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 0.38 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 0.69 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 186.67 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.13 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 0.90 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 0.54 |
| 10 | Denali Therapeutics | 3.90 Bn | 3.90 Bn | 3.51 Mn | 0.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 0.00 |
| Jun 30, 2024 | 0.00 |
| Mar 31, 2024 | 0.22 |
| Dec 31, 2023 | 0.28 |
| Sep 30, 2023 | 0.27 |
| Jun 30, 2023 | 0.25 |
| Mar 31, 2023 | 0.07 |
| Dec 31, 2022 | 0.08 |
| Sep 30, 2022 | 0.12 |
| Jun 30, 2022 | 0.11 |
| Mar 31, 2022 | 0.08 |
| Dec 31, 2021 | 0.05 |
| Sep 30, 2021 | 0.23 |
| Jun 30, 2021 | 0.23 |
| Mar 31, 2021 | 0.22 |
| Dec 31, 2020 | 0.25 |
| Sep 30, 2020 | 0.02 |
| Jun 30, 2020 | 0.04 |
| Mar 31, 2020 | 0.04 |
| Dec 31, 2019 | 0.05 |